Clinical Trial Update: Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma [Phase 2]

View source ↗

Summary

An ongoing Phase 2 clinical trial compares the combination of venetoclax and rituximab against the usual treatment (ibrutinib plus rituximab or zanubrutinib alo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoplasmacytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Rituxan (rituximab)
• Venclexta (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia | Phase 2 | Status: RECRUITING